Episode 11 of the Oncology Hour Podcast features a conversation with John Hallick on Lung cancer, MET mutations, and why patients should be aware of biomarker testing and clinical trial options.

John Hallick is a lung cancer survivor and founder of the MET Crusaders, who are a community of lung cancer patients, care givers, advocates, researchers, and physicians dedicated to helping patients with the MET alteration live normal lives.

On episode 10 of Oncology Hour, we are talking about all things pancreatic cancer with Massive Bio Co-Founder and oncologist, Dr. Arturo Loaiza-Bonilla, MD, MSEd, FACP. During the episode, a variety of pancreatic cancer topics are covered including diagnosis, treatment options, testing, and clinical research.

On episode 8 of Oncology Hour, we discuss ALK alterations in cancer and genomic testing. ALK Alterations appear in lung cancer, lymphoma, and childhood cancer. ALK inhibitors are treatments that target ALK alterations in cancer patients. Today's guests are pediatric oncologists Dr. Jason Freedman and Dr. Ted Laetsch. Dr. Jason Freedman specializes in pediatric oncology and has contributed to the development of clinical guidelines to standardize management of symptoms. Dr Ted Laetsch leads clinical and translational research evaluating novel targeted and immunotherapies for children with high-risk and often ultra-rare cancers.

On Episode 7 of Oncology Hour, we discuss Marginal Zone Lymphoma (MZL) with oncologist and lymphoma specialist Dr. Mayur Narkhede. Dr. Narkhede reviews different topics on this common Non-Hodgkin Lymphoma (NHL) such as treatment options, clinical trials, and differences from other types of lymphoma.

On the 6th episode of Oncology Hour, hematologist and myeloproliferative neoplasm (MPN) specialist Dr. Abdulraheem Yacoub, joins us to discuss myelofibrosis treatment options. mutations such as JAK, and clinical trials as an option for patients.

#myelofibrosis #MPN #clinicaltrials #JAK #genomics #precisiononcology #biomarkers

In Episode 5 of Oncology Hour, Arturo Loaiza-Bonilla, MD, MSEd, Co-Founder and Chief Medical Officer at Massive Bio joins Oncology Hour to discuss targeted therapies and how they are changing the way cancer is treated. These therapies can be offered in clinical trials. "Targeted therapy is a type of cancer treatment that targets proteins that control how cancer cells grow, divide, and spread. It is the foundation of precision medicine." - National Cancer Institute. #targetedtherapies #cancertreatment #precisiononcology #oncology #clinicaltrials

The 4th episode of Oncology Hour titled "Advances in Clinical Trials", features Dr. Jose Sandoval, MD and is hosted by Jackie Bement, Patient Advocate at Massive Bio. Jose Sandoval, MD is a hematologist & oncologist at Moffit Cancer Center. This episode features questions for Dr. Sandoval on what Lymphoma treatment options are available for patients in clinical trials, why patients should know all their options, and how services such as Massive Bio's Clinical Trial Matching System (CTMS) help patients and their oncologists identify those options.

In the 3rd episode of the Oncology Hour Podcast, we'll be discussing genomic testing for cancer with expert oncologist and Massive Bio Co-Founder Dr. Arturo Loaiza-Bonilla. Genomic or biomarker testing is the way physicians look for biomarkers (genes, proteins, and other substances) to provide more info about a cancer. Each tumor has a unique pattern of biomarkers, and some biomarkers affect which treatments to pursue and how they work. Biomarkers can also help to diagnose and monitor cancer after treatment.

In Episode 2 of Oncology Hour, we have an in-depth conversation on Lymphoma with Jose Sandoval, MD is a hematologist & oncologist at Moffit Cancer Center. During this episode, many lymphoma topics are covered such as the many different types (Mantle Cell, Burkett, Diffuse Large B-Cell, Follicular), common symptoms, risk factors, treatment options, and the benefits of clinical trials.